Nkarta, Inc.

Equities

NKTX

US65487U1088

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
11.08 USD +12.31% Intraday chart for Nkarta, Inc. -13.33% +67.95%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Canaccord Genuity Adjusts Nkarta's Price Target to $16 From $15, Keeps Buy Rating MT
HC Wainwright Adjusts Price Target on Nkarta to $22 From $20, Keeps Buy Rating MT
Nkarta Prices $240.1 Million Underwritten Offering MT
North American Morning Briefing : Tech in Focus on -2- DJ
Mizuho Securities Lowers Price Target on Nkarta to $25 From $31, Keeps Buy Rating MT
Mizuho Securities Cuts Price Target on Nkarta to $25 From $31, Maintains Buy Rating MT
HC Wainwright Adjusts Nkarta's Price Target to $20 From $22, Keeps Buy Rating MT
Raymond James Downgrades Nkarta to Outperform From Strong Buy, Price Target is $16 MT
Nkarta Trims Q4 Loss -- Shares Up After Hours MT
Nkarta, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Mizuho Securities Adjusts Price Target on Nkarta to $31 From $9 as Lupus Nephritis Program Gets Attention, Keeps Buy Rating MT
Nkarta, Inc.(NasdaqGS:NKTX) dropped from NASDAQ Biotechnology Index CI
Nkarta, Inc. Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition CI
Mizuho Securities Cuts Nkarta's Price Target to $9 From $15, Maintains Buy Rating MT
Nkarta, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
HC Wainwright Adjusts Price Target on Nkarta to $10 From $16, Keeps Buy Rating MT
Raymond James Upgrades Nkarta to Strong Buy From Outperform, Price Target is $13 MT
North American Morning Briefing : Geopolitical -2- DJ
Sector Update: Health Care Stocks Retreat in Late Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Mixed in Tuesday Afternoon Trading MT
Lupus Therapeutics Announces Partnership to Support the Evaluation of Natural Killer (NK) Cell Therapy in Lupus Nephritis CI
Nkarta's Stock Climbs 28% After FDA Approves Drug Application DJ
Nkarta Says FDA Clears IND Application for Lupus Nephritis Treatment; Planning Cost Cuts to Extend Cash Runway MT
Transcript : Nkarta, Inc. - Special Call
Chart Nkarta, Inc.
More charts
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for the treatment of patients with autoimmune diseases or hematologic malignancies. It is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. Both product candidates enable an on-demand, off-the-shelf approach involving scaled manufacturing to broaden patient access. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies. Its NKX019 oncology program is based on the potential to treat a variety of B-cell malignancies by targeting the CD19 antigen that is reliably expressed on these types of cancerous cells. Its NKX101 program is designed to enhance the power of innate NK cell biology to detect and kill cancerous cells.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
11.08 USD
Average target price
19.25 USD
Spread / Average Target
+73.66%
Consensus
  1. Stock
  2. Equities
  3. Stock Nkarta, Inc. - Nasdaq
  4. News Nkarta, Inc.
  5. Nkarta : Oppenheimer Initiates Coverage on Nkarta With Outperform Rating, $75 Price Target